Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

The bills are dead for the second year in a row, but Sun Sentinel readers still want to speak out on a plan to allow closer collaboration between Broward’s two public hospital districts.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and ...

For the past five years, conversations about prisons and how to manage them have played out as one tumultuous bout of ...

PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and ...

PIERRE — For the past five years, conversations about prisons and how to manage them have played out as one tumultuous bout ...

Bills that would mandate more transparency from pharmacy benefit managers and create a Prescription Drug Affordability board are making their way through the General Assembly. A bill that would ...

After more than a year out in the cold, the programme’s reauthorisation is a boost for rare disease therapy developers.

In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...

With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.

New FDA approval for Wakix (pitolisant) allows for the treatment of cataplexy in pediatric narcolepsy patients.